Managing Anxiety in COPD Exacerbation

Primary Approach: Optimize Medical Management First

The European Respiratory Society recommends aggressive treatment of the underlying respiratory distress as the foundation of anxiety management during COPD exacerbation, as dyspnea and anxiety are intimately linked 1, 2
Administer short-acting beta-agonists (albuterol) 2 puffs every 2-4 hours via MDI with spacer as the primary rescue medication, as recommended by the European Respiratory Society 1, 3
Add ipratropium bromide for patients with persistent symptoms, as combination therapy is superior to either agent alone, according to the European Respiratory Society 1, 4

Target oxygen saturation 90-93% using 2-4 liters by nasal cannula or 24-28% Venturi mask, as recommended by the British Thoracic Society 2
Measure arterial blood gases initially and repeat after 1 hour to monitor for hypercapnia, as suggested by the British Thoracic Society 2
Correcting hypoxemia directly reduces anxiety symptoms, according to the European Respiratory Society 5, 6

Prescribe prednisone 30-40 mg daily for 10-14 days for all hospitalized COPD exacerbations unless contraindicated, as recommended by the European Respiratory Society and the British Thoracic Society 1, 2, 3
This reduces inflammation and improves respiratory mechanics, indirectly alleviating anxiety, according to the European Respiratory Society 1

The American Thoracic Society recommends avoiding benzodiazepines due to increased all-cause mortality in severe COPD, and instead using buspirone as the preferred anxiolytic for COPD patients 7
Buspirone does not cause respiratory depression, making it safer than benzodiazepines in COPD, according to the American Thoracic Society 7

Pulmonary rehabilitation significantly reduces anxiety and depression in COPD patients, with comprehensive programs including exercise training, education, and psychosocial support showing consistent benefit, as recommended by the American Thoracic Society 8, 6, 9
Up to 40% of COPD patients have anxiety or depression, with 32% having anxiety symptoms at pulmonary rehabilitation entry, according to the American Thoracic Society 8

Review the patient's medication list for bronchospasm-inducing agents, such as non-selective beta-blockers, and consider switching to cardioselective beta-blockers or alternative therapies, as recommended by the European Respiratory Society 4
Verify proper inhaler technique before assuming treatment failure, and teach, demonstrate, and verify MDI with spacer use, according to the European Respiratory Society 4, 3